Movement Alert｜Novo Nordisk Rises 3.02% in Regular Trading, Semaglutide China Data Protection Extension and CEO China Visit Continue to Fuel Rally

Market Focus06-24

On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.

On the news front, multiple positive catalysts continue to drive the stock higher. CEO Lars Fruergaard Jorgensen recently confirmed that semaglutide's regulatory data protection period in China will extend through April next year, approximately 13 months beyond the core compound patent expiration date. This extended protection window is estimated to generate roughly $1 billion in additional stable cash flow for the company.

During his first visit to China, the CEO also announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity in Tianjin. He further disclosed that Novo Nordisk will increase BD transactions in China, maintaining active dialogue with multiple Chinese companies. Internationally, oral Wegovy recently received UK regulatory approval with clinical data showing 13.6% average weight loss over 64 weeks, reinforcing the company's global GLP-1 commercialization outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129271196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 03:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129271196","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Novo Nordisk Rises 3.02% in Regular Trading, Semaglutide China Data Protection Extension and CEO China Visit Continue to Fuel Rally","media":"Market Focus","content":"<p><p>On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.</p><p>On the news front, multiple positive catalysts continue to drive the stock higher. CEO Lars Fruergaard Jorgensen recently confirmed that semaglutide's regulatory data protection period in China will extend through April next year, approximately 13 months beyond the core compound patent expiration date. This extended protection window is estimated to generate roughly $1 billion in additional stable cash flow for the company.</p><p>During his first visit to China, the CEO also announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity in Tianjin. He further disclosed that Novo Nordisk will increase BD transactions in China, maintaining active dialogue with multiple Chinese companies. Internationally, oral Wegovy recently received UK regulatory approval with clinical data showing 13.6% average weight loss over 64 weeks, reinforcing the company's global GLP-1 commercialization outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novo Nordisk Rises 3.02% in Regular Trading, Semaglutide China Data Protection Extension and CEO China Visit Continue to Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novo Nordisk Rises 3.02% in Regular Trading, Semaglutide China Data Protection Extension and CEO China Visit Continue to Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 03:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.</p><p>On the news front, multiple positive catalysts continue to drive the stock higher. CEO Lars Fruergaard Jorgensen recently confirmed that semaglutide's regulatory data protection period in China will extend through April next year, approximately 13 months beyond the core compound patent expiration date. This extended protection window is estimated to generate roughly $1 billion in additional stable cash flow for the company.</p><p>During his first visit to China, the CEO also announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity in Tianjin. He further disclosed that Novo Nordisk will increase BD transactions in China, maintaining active dialogue with multiple Chinese companies. Internationally, oral Wegovy recently received UK regulatory approval with clinical data showing 13.6% average weight loss over 64 weeks, reinforcing the company's global GLP-1 commercialization outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1129271196","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129271196","pubTimestamp":1782242967,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.On the news front, multiple positive catalysts continue to drive the stock higher. CEO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"动向提示|诺和诺德常规交易涨3.02%司美格鲁肽中国数据保护延期及CEO访华继续助推涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.On the news front, multiple positive catalysts continue to drive the stock higher. CEO Lars Fruergaard Jorgensen recently confirmed that semaglutide's regulatory data protection period in China will extend through April next year, approximately 13 months beyond the core compound patent expiration date. This extended protection window is estimated to generate roughly $1 billion in additional stable cash flow for the company.During his first visit to China, the CEO also announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity in Tianjin. He further disclosed that Novo Nordisk will increase BD transactions in China, maintaining active dialogue with multiple Chinese companies. Internationally, oral Wegovy recently received UK regulatory approval with clinical data showing 13.6% average weight loss over 64 weeks, reinforcing the company's global GLP-1 commercialization outlook.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129271196","isCrawlerRequest":true}